2023年5月1日 · About OK-101OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease.

ok-101是利用膜锚定肽(map)技术开发的一种治疗 干眼病 的新型长效候选药物。在干眼病和角膜神经性疼痛的小鼠模型中，ok-101分别显示出抗炎和减轻疼痛的活性，并且通过药物分子中含有的脂质“锚”来对抗冲洗，从而延长ok-101在眼环境中的停留时间。

2024年2月9日 · OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical need

OK-101是 ChemR23g蛋白偶联受体 的 脂质偶联趋化素肽激动剂，通常存在于眼部负责炎症反应的免疫细胞上。 OK-101是利用膜锚定肽 (MAP)技术开发的一种治疗干眼病的新型长效候选药物。 关于 OKYO Pharma. OKYO Pharma Limited（纳斯达克股票代码：OKYO）是一家处于临床阶段的生物制药公司，致力于开发治疗 DED 和 NCP 的创新疗法，其普通股在纳斯达克资本市场上市交易。 OKYO 专注于发现和开发治疗炎症性 DED 和眼痛的新型分子。

OK-101是一种使用新型膜锚定肽 (MAP) 技术开发的长效酯化Chemerin肽类似物，由一个含10个氨基酸的肽序列（衍生自Chemerin）、一个接头成分和一个锚定脂质结构域组成。

2024年10月23日 · According to OKYO Pharma, OK-101 is the first drug candidate to enroll patients specifically diagnosed with neuropathic corneal pain in a clinical trial. The Phase 2 trial is designed as a randomized, placebo-controlled, double-masked study to treat 48 NCP patients.

Urcosimod (formerly called OK-101) Drug Candidate Urcosimod is a novel class of chemerin (ChemR23 or CMKLR1) receptor agonist that produces an anti-inflammatory and reduction in neuropathic pain. The chemerin receptor is a G protein-coupled receptor (GPCR) found on select immune, epithelial, and dorsal root ganglion/spinal cord neuronal cells.

2024年3月22日 · OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

2024年1月8日 · OK-101 has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment.

2024年7月11日 · OKYO Pharma has announced its plan to advance OK-101 into a phase 2 clinical trial of neuropathic corneal pain, expected to begin in Q3 of 2024. The announcement of this trial follows the FDA clearance of the Investigational New Drug (IND) application of OK-101 for neuropathic corneal pain back in February.